Immuneering (IMRX) Stock Forecast & Price Target

Compare

581 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMRX Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Immuneering

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMRX Stock 12 Month Forecast

Average Price Target

$16.67

▲(194.00% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Immuneering in the last 3 months. The average price target is $16.67 with a high forecast of $30.00 and a low forecast of $11.00. The average price target represents a 194.00% change from the last price of $5.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","31":"$31","7.75":"$7.75","15.5":"$15.5","23.25":"$23.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,7.75,15.5,23.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.09,8.852307692307692,10.614615384615384,12.376923076923077,14.13923076923077,15.901538461538461,17.663846153846155,19.426153846153845,21.18846153846154,22.950769230769232,24.713076923076922,26.475384615384616,28.23769230769231,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.09,7.826923076923077,8.563846153846153,9.30076923076923,10.037692307692307,10.774615384615384,11.511538461538462,12.24846153846154,12.985384615384616,13.722307692307693,14.45923076923077,15.196153846153846,15.933076923076925,{"y":16.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.09,7.390769230769231,7.691538461538461,7.992307692307692,8.293076923076923,8.593846153846155,8.894615384615385,9.195384615384615,9.496153846153845,9.796923076923077,10.097692307692308,10.39846153846154,10.69923076923077,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.1,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.09,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$16.67

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

$12

Buy

111.64%

Upside

Reiterated

12/18/25

Analysts Offer Insights on Healthcare Companies: PACS Group Inc (NYSE: PACS), Novan (NASDAQ: NOVN) and Immuneering (NASDAQ: IMRX)

Ami Fadia

Needham

$11

Buy

94.00%

Upside

Reiterated

11/13/25

Promising Potential of Immuneering's Atebimetinib: Analyst Recommends 'Buy' Rating

Geulah Livshits

Chardan Capital

$13→$20

Buy

252.73%

Upside

Reiterated

11/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HealthStream (NASDAQ: HSTM), Legend Biotech (NASDAQ: LEGN) and Immuneering (NASDAQ: IMRX)

Andrew Berens

Leerink Partners

$15

Buy

164.55%

Upside

Initiated

10/31/25

Immuneering initiated with an Outperform at LeerinkImmuneering initiated with an Outperform at Leerink

Allison Bratzel

Piper Sandler

$12

Buy

111.64%

Upside

Reiterated

09/26/25

Piper Sandler Sticks to Its Buy Rating for Immuneering (IMRX)

Jay Olson

Oppenheimer

$21→$30

Buy

429.10%

Upside

Reiterated

09/25/25

Immuneering price target raised to $30 from $21 at OppenheimerImmuneering price target raised to $30 from $21 at Oppenheimer

Michael Yee

Jefferies

$1.5→$3.5

Hold

-38.27%

Downside

Reiterated

06/25/25

Jefferies Sticks to Their Hold Rating for Immuneering (IMRX)

Jeffrey Hung

Morgan Stanley

Sell

―

Reiterated

01/13/25

Morgan Stanley Sticks to Their Sell Rating for Immuneering (IMRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

$12

Buy

111.64%

Upside

Reiterated

12/18/25

Analysts Offer Insights on Healthcare Companies: PACS Group Inc (NYSE: PACS), Novan (NASDAQ: NOVN) and Immuneering (NASDAQ: IMRX)

Ami Fadia

Needham

$11

Buy

94.00%

Upside

Reiterated

11/13/25

Promising Potential of Immuneering's Atebimetinib: Analyst Recommends 'Buy' Rating

Geulah Livshits

Chardan Capital

$13→$20

Buy

252.73%

Upside

Reiterated

11/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HealthStream (NASDAQ: HSTM), Legend Biotech (NASDAQ: LEGN) and Immuneering (NASDAQ: IMRX)

Andrew Berens

Leerink Partners

$15

Buy

164.55%

Upside

Initiated

10/31/25

Immuneering initiated with an Outperform at LeerinkImmuneering initiated with an Outperform at Leerink

Allison Bratzel

Piper Sandler

$12

Buy

111.64%

Upside

Reiterated

09/26/25

Piper Sandler Sticks to Its Buy Rating for Immuneering (IMRX)

Jay Olson

Oppenheimer

$21→$30

Buy

429.10%

Upside

Reiterated

09/25/25

Immuneering price target raised to $30 from $21 at OppenheimerImmuneering price target raised to $30 from $21 at Oppenheimer

Michael Yee

Jefferies

$1.5→$3.5

Hold

-38.27%

Downside

Reiterated

06/25/25

Jefferies Sticks to Their Hold Rating for Immuneering (IMRX)

Jeffrey Hung

Morgan Stanley

Sell

―

Reiterated

01/13/25

Morgan Stanley Sticks to Their Sell Rating for Immuneering (IMRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immuneering

1 Month

xxx

Success Rate

8/13 ratings generated profit

Average Return

+23.69%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +23.69% per trade.

3 Months

xxx

Success Rate

8/13 ratings generated profit

Average Return

+24.05%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +24.05% per trade.

1 Year

Ami FadiaNeedham

Success Rate

10/17 ratings generated profit

Average Return

+121.85%

reiterated a buy rating last month

Copying Ami Fadia's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +121.85% per trade.

2 Years

xxx

Success Rate

12/17 ratings generated profit

Average Return

+155.63%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +155.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMRX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMRX has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMRX average Analyst price target in the past 3 months is 16.67.

Each month's total comprises the sum of three months' worth of ratings.

IMRX Financial Forecast

IMRX Earnings Forecast

Next quarter’s earnings estimate for IMRX is -$0.31 with a range of -$0.38 to -$0.23. The previous quarter’s EPS was -$0.38. IMRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IMRX has Performed in-line its overall industry.

IMRX Sales Forecast

Next quarter’s sales forecast for IMRX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IMRX has Performed in-line its overall industry.

IMRX Stock Forecast FAQ

What is IMRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Immuneering’s 12-month average price target is 16.67.

What is IMRX’s upside potential, based on the analysts’ average price target?

Immuneering has 194.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMRX a Buy, Sell or Hold?

Immuneering has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Immuneering’s price target?

The average price target for Immuneering is 16.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $11.00. The average price target represents 194.00% Increase from the current price of $5.67.

What do analysts say about Immuneering?

Immuneering’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of IMRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Immuneering (IMRX) Stock Forecast & Price Target

IMRX Analyst Ratings

IMRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immuneering

IMRX Analyst Recommendation Trends

IMRX Financial Forecast

IMRX Earnings Forecast

IMRX Sales Forecast

IMRX Stock Forecast FAQ

Detailed List of Analyst Forecasts